$CASY $HOLX $BX
Casey's General Stores to replace Hologic in S&P 500 at open on 4/9
Affiliates of Blackstone (BX) and TPG Global are acquiring Hologic (HOLX) in a deal expected to be completed on or about April 7.
Strategic Brief: $MRVL Option Anomalies—Betting on S&P 500 Inclusion
Prior to the 5:15pm S&P 500 rebalancing announcement (projected to replace $HOLX), we observed aggressive late-day flows into $MRVL May $115 OTM Calls. This positioning reflects a tactical front-running of the "forced buying" effect inherent in passive index tracking. Given Marvell’s high eligibility ranking in market cap and profitability, these option strikes represent a high-gamma bet on the Index Committee’s decision. If confirmed, the resulting passive inflow could trigger a non-linear price appreciation in post-market sessions.
$CASY $HOLX $BX
Casey's General Stores to replace Hologic in S&P 500 at open on 4/9
Affiliates of Blackstone (BX) and TPG Global are acquiring Hologic (HOLX) in a deal expected to be completed on or about April 7.
A change to the S&P 500 may be imminent as Hologic is set to be acquired and taken private, creating an open slot in the index. Analysts expect a replacement to be announced soon, potentially triggering market moves among candidates.
Leading contenders include Marvell Technology, Alnylam Pharmaceuticals, and Veeva Systems, all of which meet key eligibility criteria such as market capitalization, liquidity, and sector representation. Veeva, in particular, stands out for its strong float-adjusted liquidity ratio within the healthcare sector.
Inclusion in the S&P 500 often drives increased demand for a stock, as index funds and ETFs are required to add the new constituent. As a result, potential entrants may see upward price momentum ahead of and following the announcement.
$HOLX $SPX $MID $MRVL $LNG
$OSRH Biotech company with funding and an active NDA with Sinopharm (approx. $81B in annual revenue).
The BCME Fund shall pay up to an additional $815,000,000 in milestone payments, payable directly to OSR Holdings, Inc., upon achievement of clinical, regulatory, and commercial milestones to be detailed in the Definitive Agreement.
Milestone Design Principles:
● Milestones shall be primarily weighted toward clinical and regulatory achievements, including advancement through Phase 2 and Phase 3 development and regulatory approvals.
● Purely operational milestones (e.g. patient recruitment thresholds or trial initiation alone) shall be minimized and capped.
● The milestone schedule shall be consistent with industry-standard oncology licensing transactions, adjusted to reflect the Phase-2b-ready status of VXM01.
$PFSA $SLNO $HOLX $ADTX
$OSRH 😄The price is locked in at $10
OSR Holdings, Inc. shall retain an option to issue up to $15,000,000 of OSRH common stock to the BCME Fund at a price of $10.00 per share, exercisable at OSRH’s sole discretion no earlier than six (6) months following execution of the definitive Global License Agreement (the “Equity Option”).
$PFSA $SLNO $HOLX $ADTX
$HOLX CEO retirement announced — stock at $75.65, market cap $16.9B. The filing contains no material detail beyond the headline. Leadership transition may create uncertainty; expect potential volatility.
Seeing some interesting action on $HOLX today
About 1,971 ATM $75 puts for April and June got snapped up as sweeps
April volume is way above previous open interest
Looks like a big player hedging instead of a full-blown short setup
Stock has been flat with no fresh news driving this
Implied vols on these puts are super low
They're cheap for hedging but don't offer much for selling premium
Watch for a break below $75 with more put demand before jumping in
Right now, just a signal to keep an eye on
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Valuation
Trading at 24.0× earnings vs its 23.2× historical median P/E.
Fair value ≈ $73.43 · price $76.01 today
Fair value · 4% above
Loading valuation…
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
